Fair Accountability and Innovative Research Drug Pricing Act of 2019
Latest action · May 9, 2019 Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedMay 9, 2019
- Passed SenateNot reached
- Passed HouseNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Fair Accountability and Innovative Research Drug Pricing Act of 2019
This bill requires manufacturers to report about certain price increases for prescription drugs and biological products with a wholesale cost of at least $100 per month. Such reports must include, among other information (1) the percentage price increase, (2) a justification for such increase, (3) the price history of the drug, (4) the total cost to develop the drug, and (5) the total revenue and net profit generated from the drug.
Cosponsors 7
Members who signed on, in the order they did. Signatures ran from May 9, 2019 to Sep 19, 2019; 3 are original cosponsors, there from the day it was introduced.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| R-AK | Lisa Murkowski | Original | May 9, 2019 |
| R-IN | Mike Braun | Original | May 9, 2019 |
| D-MN | Tina Smith | Original | May 9, 2019 |
| I-ME | Angus S. King Jr. | Aug 1, 2019 | |
| R-ND | John Hoeven | Aug 1, 2019 | |
| R-ND | Kevin Cramer | Sep 9, 2019 | |
| D-OH | Sherrod Brown | Sep 19, 2019 |
Committees 1
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| Senate | Health, Education, Labor, and Pensions Committee | Referred May 9, 2019 |
Actions 2
Everything that happened, newest first.
- May 9, 2019Introduced in Senate
- May 9, 2019Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Research
What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.
Printed hearings 1
Hearings whose printed record names this bill, newest first: hearings on it, and wider hearings where it came up.
| Number | Hearing | Committee | Held |
|---|---|---|---|
| S. Hrg. 116-556 | LOWER HEALTH CARE COSTS ACT136 pages | Health, Education, Labor, and Pensions Committee | Jun 18, 2019 |
CRS reports 2
Congressional Research Service work that CRS links to this bill or the law it became, newest first.
Cite it 2
Products on other subjects that cite it, usually among other measures.
| Product | Title | Kind | Published |
|---|---|---|---|
| R44832 | Frequently Asked Questions About Prescription Drug Pricing and Policy | Report | May 6, 2021 |
| R46741 | Drug Pricing and Intellectual Property: The Legislative Landscape for the 117th Congress | Report | Mar 31, 2021 |
Related bills 4
Companion bills and other measures the record links to this one.
| Bill | Title | Relationship | Latest action |
|---|---|---|---|
| S 898 | Fair Accountability and Innovative Research Drug Pricing Act of 2021 | Reintroduced Bill | Mar 23, 2021 |
| S 1131 | Fair Accountability and Innovative Research Drug Pricing Act of 2017 | Reintroduction of | May 16, 2017 |
| S 1895 | Lower Health Care Costs Act | Related bill | Jul 8, 2019 |
| HR 2296 | More Efficient Tools to Realize Information for Consumers Act | Related bill | Sep 24, 2019 |
Titles 2
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- A bill to require reporting regarding certain drug price increases, and for other purposes.
- Short Title(s) as Introduced
- Fair Accountability and Innovative Research Drug Pricing Act of 2019
Subjects
Assigned by the Library of Congress. Policy area: Health.
- Business records
- Civil actions and liability
- Congressional oversight
- Consumer affairs
- Corporate finance and management
- Government information and archives
- Government studies and investigations
- Health
- Health care costs and insurance
- Inflation and prices
- Manufacturing
- Marketing and advertising
- Medical research
- Prescription drugs
- Research and development
Text 1
Each version as it was printed, newest first.
- May 9, 2019Introduced in Senate
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.